日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Science and Health

Drugmakers cut vaccine prices for poorer nations

(Agencies)
Updated: 2011-06-06 23:07
Large Medium Small

LONDON - Several leading drugmakers are cutting their prices on potentially life-saving vaccines for people in developing countries in an effort to sustain supplies via the GAVI international vaccine alliance.

The price cuts, offered by both generic and branded drugmakers including GlaxoSmithKline, Merck, Johnson & Johnson's Crucell and Sanofi-Aventis' Sanofi Pasteur, should help the alliance narrow a $3.7 billion funding gap for its commitments up until 2015.

GSK said on Monday it would provide its Rotarix rotavirus vaccine to GAVI at a 67 percent discount to the current public price -- bringing it to $2.50 per dose, or $5 to fully immunise a child.

Merck said it will offer its Rotateq rotavirus shot at $5.00 a dose initially. "The RotaTeq price will decrease to $3.50 once the purchase volume increases to 30 million doses," it said.

Julie Gerberding, president of Merck Vaccines said long-term purchase commitments help to speed up availability of vaccines.

"Confirming volumes to be purchased will enable further price reductions as manufacturers expand production and lower costs in the future allowing for greater access," she added.

Diarrhoea is one of the top two killers of children under five worldwide and rotavirus is the leading cause of severe diarrhoeal disease in children. Each year, rotavirus-related diarrhoea kills more than 500,000 children.

In 2009, the WHO recommended that all countries should include rotavirus vaccines in national vaccination programmes, but many poorer countries struggle to afford them.

GAVI, which funds bulk-buy vaccination programmes for nations that can't afford shots at Western prices, has committed to help fund rotavirus vaccine introduction in at least 40 of the world's poorest countries by 2015.

But the alliance is facing a shortfall of $3.7 billion to fund it projects through to 2015, and has been seeking extra donor money and price cuts from drug firms to close that gap. It has a pledging conference in London on June 13.

"These are promising offers that demonstrate industry commitment to work towards affordable and sustainable prices," Helen Evans, GAVI's interim chief executive, said in a statement.

GSK said it had offered to supply up to 125 million doses of Rotarix over five years at an approximately 95 percent price cut from the Western market price.

"Whilst most babies in the world will get rotavirus at some point, those in developing countries do not have access to the medical care they need which means millions of babies die unnecessarily," GSK's CEO Andrew Witty said in a statement.

He said the British drugmaker was committed to finding new ways to get urgently needed vaccines to children in poor countries.

Evans said that if rotavirus vaccine could be purchased this year at $2.50 a dose, the impact on public health could be significant and would allow GAVI to save approximately $500 million through to 2020, or about $140 million through to 2015.

The price GAVI pays for pentavalent vaccines, which protect against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b, will also be cut by the India-based firms Serum Institute and Panacea Biotec.

Serum, which had already cut its price to $1.75 a dose, said it would "continue to provide the most competitive pricing," while Panacea said it would cut its price by up to 15 percent.

Crucell and Sanofi Pasteur said they would extend GAVI prices on their pentavalent vaccines to 16 countries who are moving on from GAVI support to begin buying shots themselves.

Sanofi Pasteur said this would also apply to its yellow fever vaccine and a rotavirus vaccine being developed by its Indian subsidiary Shantha.

Merck also announced it will offer GAVI its Gardasil shot, which protects the human papillomavirus (HPV) that causes cervical cancer, at a discounted price of $5 per dose -- a 67 percent reduction on the current public price.

Although GAVI has not yet committed to funding HPV vaccines, it said they were part of its investment strategy and it hoped "to see further price reductions." More than 90 percent of deaths from cervical cancer now occur in developing countries, killing 200,000 women a year.

分享按鈕
主站蜘蛛池模板: 久久99热这里只频精品6中文字幕 | 成人在线免费小视频 | 99pao成人国产永久免费视频 | 成年免费视频 | 午夜网页 | 三级视频网址 | 久久华人 | 日本一道本视频 | 中文字幕成人乱码在线电影 | 国产精品一区久久久 | 国产电影一区二区 | 五月亭亭激情五月 | 成人天堂网 | 欧美日韩国产在线人成dvd | 国产在线小视频 | 国产网站免费视频 | 韩国在线精品福利视频在线观看 | 污污成人一区二区三区四区 | 99久久产在线 | 天天射天天干 | 色综合久久中文字幕网 | 亚洲国产精品热久久 | 天天拍天天干 | 午夜视频在线免费播放 | 亚洲成人av在线 | www欧美| 国产视频大全 | 日韩毛片网 | 91在线亚洲精品专区 | 加勒比精品久久一区二区三区 | 久久精品久久久久电影 | 国产黄色在线观看 | 理论片91 | 国产你懂得 | 久久国产精品久久 | 国产色婷婷精品综合在线观看 | 亚洲精品视频观看 | 天天操天天射天天舔 | 久久综合九色综合桃花 | 亚洲欧美另类日韩 | 久久精品免费 |